NR1H4 and steatosis: However, there is a possibility that the improvement in steatosis by FXR-ligands are due to not only to inhibition of lipogenesis but also to enhancement of lipolysis, because there is molecular crosstalk between the FXR and peroxisome proliferator-activated receptor-α (PPARα; NR1C1) (Fig. 1).